ReviewDigestive diseases and sciences2018
Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
Review in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.Digestion · 2023Pooled it
- Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2021Pooled it
- A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.Clinical pharmacokinetics · 2020Pooled it
- Pooled it
- Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.British journal of clinical pharmacology · 2022Trial
- Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials.EClinicalMedicine · 2026Article
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus.BMC microbiology · 2025Article
- The Effect of Tegoprazan on Serum Gastrin Levels and the Development of Hypergastrinemia in the Maintenance Treatment for Gastroesophageal Reflux Disease: Comparison to Lansoprazole.Journal of neurogastroenterology and motility · 2025Article
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.Current gastroenterology reports · 2024Review
- Amelioration of obsessive-compulsive disorder by intracellular acidification of cortical neurons with a proton pump inhibitor.Translational psychiatry · 2024Article
- New Perspectives in Endoscopic Treatment of Gastroesophageal Reflux Disease.Diagnostics (Basel, Switzerland) · 2023Review
- Research on antibiotic resistance inFrontiers in microbiology · 2023Article
- Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.Przeglad gastroenterologiczny · 2023Review
- Substituent-Dependent Divergent Synthesis of 2-(3-Amino-2,4-dicyanophenyl)pyrroles, Pyrrolyldienols and 3-Amino-1-acylethylidene-2-cyanopyrrolizines via Reaction of Acylethynylpyrroles with Malononitrile.Molecules (Basel, Switzerland) · 2022Article
- Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders.Gastroenterology & hepatology · 2022Article
- Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review.Annals of medicine and surgery (2012) · 2022Review
- The efficacy of vonoprazan combined with different dose amoxicillin on eradication ofAnnals of translational medicine · 2022Article
- Efficacy and safety comparison ofTherapeutic advances in gastroenterology · 2022Article
- Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.Helicobacter · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K
Indexed as
Identifiers
29282636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.